Everest Organics develops anti-fungal API ‘Posaconazole’

25 May 2021 Evaluate

Everest Organics has successfully developed an anti-fungal API ‘Posaconazole’ meant to treat black fungus patients, at the lab scale in the existing R & D facility of company. Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients popularly known as Black Fungus in post Covid complications.  Further, the company is in advance stage of commercializing the same.

The company has successfully in near past launched and commercialized 'Oseltamivir' and 'Remdesivir' both being used for Covid-19. Now it is more confident and are poised for development of more niche products in the quickest span of time because of its R&D strength.

Everest Organics is a fast growing API and Bulk drug manufacturing company with world class facility and it is committed to manufacturing excellent quality products and customer service.

Everest Organics Share Price

118.90 -3.05 (-2.50%)
04-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1455.00
Dr. Reddys Lab 5730.85
Cipla 1459.75
Zydus Lifesciences 1007.20
Lupin 1564.60
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.